{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:28:15Z","timestamp":1760909295645,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00277-021-04619-4","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:14:59Z","timestamp":1627704899000},"page":"2961-2968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study"],"prefix":"10.1007","volume":"100","author":[{"given":"Xiao-Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Lai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-8653","authenticated-orcid":false,"given":"Hui-Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Lymphoma Committee, Chinese Anti-Cancer Association (CACA)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"issue":"3","key":"4619_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","volume":"2","author":"I Barista","year":"2001","unstructured":"Barista I, Romaguera JE, Cabanillas F (2001) Mantle-cell lymphoma. Lancet Oncol 2(3):141\u2013148","journal-title":"Lancet Oncol"},{"issue":"5","key":"4619_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/01.cco.0000174039.69656.2b","volume":"17","author":"ME Williams","year":"2005","unstructured":"Williams ME, Densmore JJ (2005) Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 17(5):425\u2013431","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"4619_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hon.767","volume":"24","author":"F Bertoni","year":"2006","unstructured":"Bertoni F, Rinaldi A, Zucca E, Cavalli F (2006) Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 24(1):22\u201327","journal-title":"Hematol Oncol"},{"issue":"2","key":"4619_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-003-0774-2","volume":"83","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Hiddemann W (2004) Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 83(2):71\u201377","journal-title":"Ann Hematol"},{"issue":"26","key":"4619_CR5","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE (2005) Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23(26):6409\u20136414","journal-title":"J Clin Oncol"},{"issue":"11","key":"4619_CR6","first-page":"1580","volume":"90","author":"S Vigouroux","year":"2005","unstructured":"Vigouroux S, Gaillard F, Moreau P, Harousseau JL, Milpied N (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 90(11):1580\u20131582","journal-title":"Haematologica"},{"issue":"10","key":"4619_CR7","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/cncr.20234","volume":"100","author":"CS Tam","year":"2004","unstructured":"Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF (2004) Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer 100(10):2181\u20132189","journal-title":"Cancer"},{"issue":"2","key":"4619_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","volume":"16","author":"D Decaudin","year":"1998","unstructured":"Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, Bayle C, Carde P, Bendahmane B, Hayat M, Munck JN (1998) Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16(2):579\u2013583","journal-title":"J Clin Oncol"},{"issue":"5","key":"4619_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3109\/10428190109097721","volume":"42","author":"BJ Cohen","year":"2001","unstructured":"Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelentez A (2001) Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42(5):1015\u20131022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4619_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F (1996) Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14(4):1262\u20131268. https:\/\/doi.org\/10.1200\/JCO.1996.14.4.1262","journal-title":"J Clin Oncol"},{"key":"4619_CR11","doi-asserted-by":"crossref","unstructured":"Lossos IS, Paltiel O, Polliack A (1999) Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas. Leuk Lymphoma 33 (null):155\u2013160","DOI":"10.3109\/10428199909093737"},{"issue":"4","key":"4619_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/10428190400029841","volume":"46","author":"DW Thomas","year":"2005","unstructured":"Thomas DW, Owen RG, Johnson SA, Hillmen P, Seymour JF, Wolf MM, Rule SA (2005) Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 46(4):549\u2013552","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4619_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2007","unstructured":"Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18(1):116\u2013121","journal-title":"Ann Oncol"},{"issue":"30","key":"4619_CR14","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O\u2019Connor OA, Shi H, Boral AL, Goy A (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867\u20134874","journal-title":"J Clin Oncol"},{"issue":"4","key":"4619_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(4):667\u2013675","journal-title":"J Clin Oncol"},{"issue":"13","key":"4619_CR16","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24(13):2105\u20132112","journal-title":"J Clin Oncol"},{"issue":"4","key":"4619_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O'Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 23(4):676\u2013684","journal-title":"J Clin Oncol"},{"issue":"9","key":"4619_CR18","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","volume":"111","author":"S Hewamana","year":"2008","unstructured":"Hewamana S, Alghazal S, Lin T, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C (2008) The NF-\u03baB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111(9):4681\u20134689","journal-title":"Blood"},{"issue":"5","key":"4619_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1600-0609.2004.00406.x","volume":"74","author":"M Duechler","year":"2005","unstructured":"Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P (2005) In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol 74(5):407\u2013417","journal-title":"Eur J Haematol"},{"issue":"4","key":"4619_CR20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddeman W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"issue":"7","key":"4619_CR21","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105(7):2677\u20132684","journal-title":"Blood"},{"issue":"1","key":"4619_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2141.2009.07836.x","volume":"147","author":"B Pm","year":"2009","unstructured":"Pm B, P F, HM L, N H, SL G, ON K, NJ B, MR S, A D, BW C, (2009) Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 147(1):89\u201396","journal-title":"Br J Haematol"},{"issue":"10","key":"4619_CR23","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, H\u00e4nel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, B\u00f6ck HP, Wandt H, Unterhalt M, Hiddemann W (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064\u20133071","journal-title":"Blood"},{"issue":"6","key":"4619_CR24","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Br\u00fcggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling M, Hiddemann W, Siebert R, Dreger P, Kneba M (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107(6):2271\u20132278","journal-title":"Blood"},{"issue":"5","key":"4619_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2165\/00003495-199345050-00009","volume":"45","author":"SR Ross","year":"1993","unstructured":"Ross SR, McTavish D, Faulds D (1993) Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 45(5):737\u2013759","journal-title":"Drugs"},{"issue":"15","key":"4619_CR26","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim S-Z, Welslau M, Hecker R, Kofahl-Krause D, Josten K-M, D\u00fcrk H, Rost A, Neise M, von Gr\u00fcnhagen U, Chow KU, Hansmann M-L, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389","journal-title":"J Clin Oncol"},{"issue":"10","key":"4619_CR27","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807\u20132812","journal-title":"Blood"},{"key":"4619_CR28","doi-asserted-by":"publisher","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJM, Dreyling M (2020) Mantle cell lymphoma. Crit Rev Oncol Hematol 153:103038. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103038","DOI":"10.1016\/j.critrevonc.2020.103038"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04619-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T14:03:51Z","timestamp":1636985031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04619-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4619"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04619-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"2 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}